dalteparin has been researched along with Chronic Kidney Diseases in 21 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " To challenge this premise, we evaluated if deep vein thrombosis (DVT) prophylaxis with dalteparin sodium confers an excessive anticoagulant effect in critically ill patients with severe renal insufficiency." | 9.13 | Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. ( Albert, M; Anderson, D; Cook, D; Crowther, M; Douketis, J; Fowler, R; Freitag, A; Geerts, W; Granton, J; Guyatt, G; Hébert, P; Heels-Ansdell, D; Marshall, J; Meade, M; Pagliarello, G; Rabbat, C; Skrobik, Y; Zytaruk, N, 2008) |
| "We compared the incidence of clinically significant bleeding in patients with CKD receiving therapeutic doses of dalteparin to that of patients with CKD receiving therapeutic doses of UFH." | 7.83 | Treatment with Dalteparin is Associated with a Lower Risk of Bleeding Compared to Treatment with Unfractionated Heparin in Patients with Renal Insufficiency. ( Billett, HH; Calvo, M; Kushnir, M; Park, D; Sinnet, M; Solorzano, C; Southern, W, 2016) |
| " To challenge this premise, we evaluated if deep vein thrombosis (DVT) prophylaxis with dalteparin sodium confers an excessive anticoagulant effect in critically ill patients with severe renal insufficiency." | 5.13 | Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. ( Albert, M; Anderson, D; Cook, D; Crowther, M; Douketis, J; Fowler, R; Freitag, A; Geerts, W; Granton, J; Guyatt, G; Hébert, P; Heels-Ansdell, D; Marshall, J; Meade, M; Pagliarello, G; Rabbat, C; Skrobik, Y; Zytaruk, N, 2008) |
| "We compared the incidence of clinically significant bleeding in patients with CKD receiving therapeutic doses of dalteparin to that of patients with CKD receiving therapeutic doses of UFH." | 3.83 | Treatment with Dalteparin is Associated with a Lower Risk of Bleeding Compared to Treatment with Unfractionated Heparin in Patients with Renal Insufficiency. ( Billett, HH; Calvo, M; Kushnir, M; Park, D; Sinnet, M; Solorzano, C; Southern, W, 2016) |
| " With the availability of anti-Xa assays, future reversal recommendations of enoxaparin associated bleeds using protamine sulfate should include the initial anti-Xa assay as a guide for the dosing regimen." | 1.51 | Protamine sulfate for the reversal of enoxaparin associated hemorrhage beyond 12 h. ( Adamski, JH; Barcelona, RA; Gibbons, J; Janko, MR; Lauer, BR; Nelson, RA; Ravi, G, 2019) |
| " However, several international guidelines recommend the same preemptive dosage reduction for all therapeutic dose LMWHs prescribed in renal insufficient patients, to ensure that there is no accumulation of anticoagulant activity and increased risk of bleeding." | 1.46 | Empirically Reduced Dosages of Tinzaparin in Patients with Moderate-to-Severe Renal Insufficiency Lead to Inadequate Anti-Xa Levels. ( Henskens, YMC; Meertens, NEL; Olie, RH; Ten Cate, H, 2017) |
| " These NCCN Guidelines Insights summarize the data supporting new dosing recommendations for VTE prophylaxis in obese patients with cancer." | 1.42 | Cancer-Associated Venous Thromboembolic Disease, Version 1.2015. ( Ashrani, A; Bockenstedt, PL; Chesney, C; Eby, C; Engh, AM; Fanikos, J; Fenninger, RB; Fogerty, AE; Gao, S; Goldhaber, SZ; Hendrie, P; Holmstrom, B; Kuderer, N; Lee, A; Lee, JT; Lovrincevic, M; McMillian, N; Millenson, MM; Neff, AT; Ortel, TL; Paschal, R; Shattil, S; Siddiqi, T; Smock, KJ; Soff, G; Streiff, MB; Wang, TF; Yee, GC; Zakarija, A, 2015) |
| " Inappropriate dosing of LMWH suggested by subtherapeutic and supratherapeutic antifactor Xa levels were very high in patients with different levels of kidney dysfunction." | 1.38 | Are low-molecular-weight heparins appropriately dosed in patients with CKD stage 3 to 5? ( Altun, B; Arici, M; Buyukasik, Y; Erdem, Y; Kocak, T; Yildirim, T; Yilmaz, R, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.76) | 29.6817 |
| 2010's | 15 (71.43) | 24.3611 |
| 2020's | 5 (23.81) | 2.80 |
| Authors | Studies |
|---|---|
| Sain, M | 1 |
| Kovacic, V | 1 |
| Radic, J | 1 |
| Ljutic, D | 1 |
| Jelicic, I | 1 |
| Cornelis, T | 1 |
| Broers, NJ | 1 |
| Titulaer, DC | 1 |
| Henskens, YM | 1 |
| van Oerle, R | 1 |
| van der Sande, FM | 1 |
| Spronk, HM | 1 |
| Vink, H | 1 |
| Leunissen, KM | 1 |
| ten Cate, H | 2 |
| Kooman, JP | 1 |
| Fontcuberta Boj, J | 1 |
| Wang, TF | 2 |
| Grubic, N | 1 |
| Carrier, M | 1 |
| Canney, M | 1 |
| Delluc, A | 1 |
| Hundemer, GL | 1 |
| Knoll, G | 1 |
| Lazo-Langner, A | 1 |
| Massicotte-Azarniouch, D | 1 |
| Tanuseputro, P | 1 |
| Sood, MM | 1 |
| Mattioli, M | 1 |
| Fustini, E | 1 |
| Gennarini, S | 1 |
| Nachega, JB | 1 |
| Ishoso, DK | 1 |
| Otokoye, JO | 1 |
| Hermans, MP | 1 |
| Machekano, RN | 1 |
| Sam-Agudu, NA | 1 |
| Bongo-Pasi Nswe, C | 1 |
| Mbala-Kingebeni, P | 1 |
| Madinga, JN | 1 |
| Mukendi, S | 1 |
| Kolié, MC | 1 |
| Nkwembe, EN | 1 |
| Mbuyi, GM | 1 |
| Nsio, JM | 1 |
| Mukeba Tshialala, D | 1 |
| Tshiasuma Pipo, M | 1 |
| Ahuka-Mundeke, S | 1 |
| Muyembe-Tamfum, JJ | 1 |
| Mofenson, L | 1 |
| Smith, G | 1 |
| Mills, EJ | 1 |
| Mellors, JW | 1 |
| Zumla, A | 1 |
| Mavungu Landu, DJ | 1 |
| Kayembe, JM | 1 |
| Rydzewska-Rosolowska, A | 1 |
| Gozdzikiewicz-Lapinska, J | 1 |
| Borawski, J | 1 |
| Koc-Zorawska, E | 1 |
| Mysliwiec, M | 1 |
| Naumnik, B | 1 |
| Lauer, BR | 1 |
| Nelson, RA | 1 |
| Adamski, JH | 1 |
| Gibbons, J | 1 |
| Janko, MR | 1 |
| Ravi, G | 1 |
| Barcelona, RA | 1 |
| Saheb Sharif-Askari, F | 1 |
| Syed Sulaiman, SA | 1 |
| Saheb Sharif-Askari, N | 1 |
| Al Sayed Hussain, A | 1 |
| Railey, MJ | 1 |
| Streiff, MB | 1 |
| Holmstrom, B | 1 |
| Ashrani, A | 1 |
| Bockenstedt, PL | 1 |
| Chesney, C | 1 |
| Eby, C | 1 |
| Fanikos, J | 1 |
| Fenninger, RB | 1 |
| Fogerty, AE | 1 |
| Gao, S | 1 |
| Goldhaber, SZ | 1 |
| Hendrie, P | 1 |
| Kuderer, N | 1 |
| Lee, A | 1 |
| Lee, JT | 1 |
| Lovrincevic, M | 1 |
| Millenson, MM | 1 |
| Neff, AT | 1 |
| Ortel, TL | 1 |
| Paschal, R | 1 |
| Shattil, S | 1 |
| Siddiqi, T | 1 |
| Smock, KJ | 1 |
| Soff, G | 1 |
| Yee, GC | 1 |
| Zakarija, A | 1 |
| McMillian, N | 1 |
| Engh, AM | 1 |
| Triscott, J | 1 |
| Mercer, S | 1 |
| Tian, PG | 1 |
| Dobbs, B | 1 |
| Hoffmann, P | 1 |
| Keller, F | 1 |
| Shorr, AF | 1 |
| Eriksson, BI | 1 |
| Jaffer, AK | 1 |
| Smith, J | 1 |
| Yildirim, T | 1 |
| Kocak, T | 1 |
| Buyukasik, Y | 1 |
| Yilmaz, R | 1 |
| Altun, B | 1 |
| Erdem, Y | 1 |
| Arici, M | 1 |
| Dorsch, O | 1 |
| Krieter, DH | 1 |
| Lemke, HD | 1 |
| Fischer, S | 1 |
| Melzer, N | 1 |
| Sieder, C | 1 |
| Bramlage, P | 1 |
| Harenberg, J | 1 |
| Kwofie, MK | 1 |
| Wilson, JA | 1 |
| Park, D | 1 |
| Southern, W | 1 |
| Calvo, M | 1 |
| Kushnir, M | 1 |
| Solorzano, C | 1 |
| Sinnet, M | 1 |
| Billett, HH | 1 |
| Douketis, J | 1 |
| Cook, D | 1 |
| Meade, M | 1 |
| Guyatt, G | 1 |
| Geerts, W | 1 |
| Skrobik, Y | 1 |
| Albert, M | 1 |
| Granton, J | 1 |
| Hébert, P | 1 |
| Pagliarello, G | 1 |
| Marshall, J | 1 |
| Fowler, R | 1 |
| Freitag, A | 1 |
| Rabbat, C | 1 |
| Anderson, D | 1 |
| Zytaruk, N | 1 |
| Heels-Ansdell, D | 1 |
| Crowther, M | 1 |
| Helfer, H | 1 |
| Siguret, V | 1 |
| Mahé, I | 1 |
| Yeung, J | 1 |
| Dix, CHK | 1 |
| Ritchie, AG | 1 |
| Kow, M | 1 |
| Chen, VMY | 1 |
| Olie, RH | 1 |
| Meertens, NEL | 1 |
| Henskens, YMC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-center, Prospective, Open-label, 8-weeks Study to Investigate the Efficacy, Safety and Pharmacokinetics of Certoparin (3000 IU Anti-Xa Bolus, With the Option to Titrate Dose)in the Prophylaxis of Clotting in the Extracorporeal Circuit in Patients [NCT01179620] | Phase 3 | 109 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Dalteparin's Influence on Renally Compromised: Anti-Ten-A Study (DIRECT)[NCT00138099] | 140 participants (Actual) | Observational | 2004-07-31 | Completed | |||
| Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses[NCT02719418] | 28 participants (Actual) | Observational | 2016-02-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for dalteparin and Chronic Kidney Diseases
| Article | Year |
|---|---|
New frontiers with bemiparin: use in special populations.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Child; Female; Fibrinolytic Agents; Heparin, Low-Mol | 2010 |
Retroperitoneal haematoma associated with enoxaparin use in an elderly woman with chronic kidney disease.
Topics: Aged, 80 and over; Anticoagulants; Aspirin; Enoxaparin; Erythrocyte Transfusion; Female; Hematoma; H | 2015 |
Increased major bleeding risk in patients with kidney dysfunction receiving enoxaparin: a meta-analysis.
Topics: Anticoagulants; Cardiovascular Diseases; Enoxaparin; Glomerular Filtration Rate; Hemorrhage; Humans; | 2012 |
Tinzaparin Sodium Pharmacokinetics in Patients with Chronic Kidney Disease: Practical Implications.
Topics: Fibrinolytic Agents; Hemorrhage; Humans; Renal Elimination; Renal Insufficiency, Chronic; Risk Adjus | 2020 |
2 trials available for dalteparin and Chronic Kidney Diseases
15 other studies available for dalteparin and Chronic Kidney Diseases
| Article | Year |
|---|---|
What are the lowest doses of low molecular weight heparin for effective and safe hemodialysis in different subgroups of patients?
Topics: Aged; Anticoagulants; Female; Humans; Male; Middle Aged; Nadroparin; Renal Dialysis; Renal Insuffici | 2014 |
Effects of ultrapure hemodialysis and low molecular weight heparin on the endothelial surface layer.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dialysis Solutions; E-Selectin; Endothelium, Vascular; Fema | 2014 |
Risk of venous thromboembolism or hemorrhage among individuals with chronic kidney disease on prophylactic anticoagulant after hip or knee arthroplasty.
Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Heparin, Low-M | 2023 |
Heart transplant recipient patient with COVID-19 treated with tocilizumab.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anticoagulants; Cardiomyopathy, Dilated; C | 2020 |
Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo.
Topics: Adolescent; Adult; Asymptomatic Diseases; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatme | 2020 |
Unexpected and striking effect of heparin-free dialysis on cytokine release.
Topics: Activins; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Chemokine CCL2; Endostatins; E | 2017 |
Protamine sulfate for the reversal of enoxaparin associated hemorrhage beyond 12 h.
Topics: Abdominal Wall; Aged; Anticoagulants; Drug Administration Schedule; Emergency Service, Hospital; Eno | 2019 |
Adverse outcomes of anticoagulant use among hospitalized patients with chronic kidney disease: a comparison of the rates of major bleeding events between unfractionated heparin and enoxaparin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Enoxaparin; Female; Hemorrhage; Hepa | 2014 |
Cancer-Associated Venous Thromboembolic Disease, Version 1.2015.
Topics: Adult; Anticoagulants; Body Mass Index; Body Weight; Dalteparin; Enoxaparin; Fondaparinux; Heparin; | 2015 |
Impact of stage 3B chronic kidney disease on thrombosis and bleeding outcomes after orthopedic surgery in patients treated with desirudin or enoxaparin: insights from a randomized trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Drug Adm | 2012 |
Are low-molecular-weight heparins appropriately dosed in patients with CKD stage 3 to 5?
Topics: Aged; Aged, 80 and over; Anticoagulants; Biomarkers; Blood Coagulation Tests; Drug Dosage Calculatio | 2012 |
A potential risk from under-recognized perioperative anticoagulation from dalteparin used for extracorporeal circuit anticoagulation during hemodialysis.
Topics: Anticoagulants; Dalteparin; Extracorporeal Circulation; Humans; Renal Dialysis; Renal Insufficiency, | 2019 |
Treatment with Dalteparin is Associated with a Lower Risk of Bleeding Compared to Treatment with Unfractionated Heparin in Patients with Renal Insufficiency.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Female; Glomerular Filtration Rate; Hemorrhage; | 2016 |
Tinzaparin for venous thromboembolism in patients with renal impairment: a single-centre, prospective pilot study.
Topics: Aged; Anticoagulants; Heparin, Low-Molecular-Weight; Humans; Pilot Projects; Prospective Studies; Re | 2023 |
Empirically Reduced Dosages of Tinzaparin in Patients with Moderate-to-Severe Renal Insufficiency Lead to Inadequate Anti-Xa Levels.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Factor X Deficiency; Factor Xa; Female; Fibrinolytic | 2017 |